Frizzled-10 and cancer progression: Is it a new prognostic marker?
Metrics: PDF 1194 views | HTML 1939 views | ?
Maria Principia Scavo1,*, Livia Fucci2,*, Lucia Caldarola2, Anita Mangia3, Amalia Azzariti4, Giovanni Simone2, Giampietro Gasparini5 and Silke Krol1,6
1Translational Nanotechnology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
2Pathology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
3Functional Biomorphology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
4Experimental Pharmacology Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
5Direzione Scientifica, IRCCS Istituto Tumori “Giovanni Paolo II”, 70124 Bari, Italy
6Fondazione IRCCS Istituto Neurologico “Carlo Besta”, 20133 Milan, Italy
*These authors contributed equally to this work
Maria Principia Scavo, email: [email protected]
Silke Krol, email: [email protected]
Keywords: colon cancer; melanoma; gastric cancer; frizzled-10; prognostic marker
Received: September 08, 2017 Accepted: November 15, 2017 Published: December 12, 2017
Frizzled (FZD) proteins, a family of Wnt receptors, are involved in carcinogenesis in different organs. One interesting FZD protein is FZD-10 highly expressed in embryogenesis but completely absent in the membrane or cytosol of healthy proliferated cells. We studied in detail the expression level and the location of Frizzled-10 protein in different cancerous tissues, such as colon, melanoma and gastric cancer and in function of different staging of the tumor and in metastases. We observed a correlation between cancer evolution and FZD-10 expression, and localization of protein during carcinogenesis. In colon, we have an increase of cytoplasmic FZD-10 expression from hyperplastic mucosa to metastatic tissues, while the amount in the nucleus decreases significantly in T3 and T4 staging tumors as well as in metastases. In melanoma and gastric cancer, we observed the opposite trend of FZD-10 protein in the cytosol but both show a decrease in the T3 and T4 stage of the tumor and in metastases. However, the decrease is less prominent in gastric cancer.
Our findings indicate an important role of FZD-10 in tumor progression especially in the later stages of tumor. The nuclear expression of FZD-10 or its absence can give a new tool for tumor staging to pathologists. For target therapy, at least for colon cancer, the high presence of FZD-10 in the later stages of tumor progression and the absence in healthy tissue present a promising new approach.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.